Spark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
Results of Operations and Financial Condition.
On February 19, 2019, Spark Therapeutics, Inc. issued a press release announcing unaudited consolidated financial results for the year ended December 31, 2018. A copy of the press release is being filed as Exhibit99.1 to this Current Report on Form8-K.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|
Item 2.02. |
Financial Statements and Exhibits. |
(d) Exhibits
The following exhibit relating to Item 2.02 shall be deemed to be furnished, and not filed:
Spark Therapeutics, Inc. Exhibit
EX-99.1 2 spark-exhibit991fullyear20.htm EXHIBIT 99.1 EARNINGS PRESS RELEASE Exhibit Exhibit 99.1 Spark Therapeutics Reports 2018 Financial Results and Recent Business ProgressPHILADELPHIA,…
To view the full exhibit click here
About Spark Therapeutics, Inc. (NASDAQ:ONCE)
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder.
